Shares of Alderley Park-based Redx Pharma rose about 12% as the clinical-stage biotechnology company announced that three abstracts submitted by the firm “have been accepted for presentation as posters at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, 5 – 10 April 2024.”
Redx said: “One poster investigating Redx’s lead asset zelasudil (RXC007), a selective ROCK 2 inhibitor, currently in Phase 2a development for Idiopathic Pulmonary Fibrosis (IPF) which has shown promising preclinical efficacy in a range of models, will be presented in collaboration with the company’s research partner, the Garvan Institute of Medical Research, Australia.
“The data from preclinical models of pancreatic cancer shows the potential of zelasudil to increase survival in mouse models of pancreatic ductal adenocarcinoma (PDAC), when used in combination with current standard of care.
“Redx will also present two posters on zamaporvint (RXC004) a potent and selective porcupine inhibitor targeting Wnt-ligand dependent cancers, currently in Phase 2 development in hard-to-treat tumors.
“The first poster highlights the potential to combine zamaporvint with MAPK pathway inhibitors in gastrointestinal cancer models showing that co-inhibition of these pathways leads to synergistic effects in vitro and enhanced efficacy in vivo.
“The second poster, entitled: Final results of the first-in-human study of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with advanced solid tumors, will discuss final data from all the Phase 1 modules of the programme. The abstract from this second poster will be available on 5 April 2024 at 3:00pm ET.”
Redx Pharma chief scientific officer said: “To have three poster presentations at a prestigious conference such as AACR is a testament to the strength of our portfolio.
“With the potential to expand the indications for zelasudil beyond IPF and interstitial lung diseases into fibrotic cancers such as pancreatic; and the expansion of potential combination treatments with zamaporvint for hard-to-treat aggressive tumours, we are optimistic about the utility of our drugs for a number of underserved patient populations.”